Screener
Crinetics Pharmaceuticals CRNX Business Segments — Other Research and Development Programs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept crnx:OtherResearchAndDevelopmentPrograms.
The source filing: Crinetics Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:25 PM EST
- Fiscal year
- FY2025
- Accession
- 0001658247-26-000012
| Line item | Year ended December 31, 2025 | Year ended December 31, 2024 | Year ended December 31, 2023 |
|---|---|---|---|
| Research and development expenses | |||
| Paltusotine | (68,337) | (51,229) | (46,772) |
| Atumelnant | (48,131) | (24,524) | (13,118) |
| Other research and development programs | (33,322) | (26,010) | (20,421) |
| Research and development personnel expenses | (102,677) | (70,772) | (53,446) |
| Research and development stock-based compensation | (50,344) | (40,667) | (22,633) |
| Other research and development (1) | (29,247) | (26,954) | (12,137) |
| Total research and development expenses | (332,058) | (240,156) | (168,527) |
Item 16. Form 10-K Summary
FAQ
- What is Crinetics Pharmaceuticals's business segments — other research and development programs?
- Crinetics Pharmaceuticals (CRNX) reported business segments — other research and development programs of $8.33M in Q4 2025.
- How has Crinetics Pharmaceuticals's business segments — other research and development programs changed year-over-year?
- Crinetics Pharmaceuticals's business segments — other research and development programs increased by 28.1% year-over-year, from $6.5M to $8.33M.
- What is the long-term trend for Crinetics Pharmaceuticals's business segments — other research and development programs?
- Over 2 years (2023 to 2025), Crinetics Pharmaceuticals's business segments — other research and development programs has grown at a 27.7% compound annual growth rate (CAGR), from $20.42M to $33.32M.
- What does business segments — other research and development programs mean?
- Aggregates the research and development expenditures for early-stage or secondary pipeline assets not specifically categorized under primary lead programs. This metric tracks the company's investment in diversifying its therapeutic portfolio and long-term innovation pipeline. It provides visibility into the breadth of the company's R&D efforts beyond its flagship clinical candidates.
Ask your AI about Crinetics Pharmaceuticals's business segments — other research and development programs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude